Shockwave Therapy for Morton's Neuroma: What Does the Evidence Show?

Morton's neuroma is one of the forefoot conditions for which shockwave therapy has direct randomized, sham-controlled clinical evidence. The available trials report meaningful pain improvement after ESWT, but the evidence base is still small and ultrasound studies have not demonstrated that shockwave reduces neuroma size.

The most defensible interpretation is therefore that ESWT can reduce symptoms in selected patients with Morton's neuroma, not that it physically removes or shrinks the neuroma.

Start with the right diagnosis

Shockwave should be considered only after the underlying diagnosis is identified. "Metatarsalgia" by itself is not a sufficiently specific treatment indication. Ball-of-foot pain can come from Morton's neuroma, intermetatarsal bursitis, plantar plate injury, MTP joint disease, a stress fracture, sesamoid pathology or mechanical overload, and the shockwave trials discussed here studied Morton's neuroma specifically. How these conditions are told apart is covered in Morton's neuroma vs. metatarsalgia vs. intermetatarsal bursitis and plantar plate injury vs. metatarsalgia.

The 2009 randomized double-blind sham-controlled trial

In a double-blind randomized sham-controlled trial of 25 patients with chronic painful interdigital neuroma, active ESWT significantly reduced pain through 12 weeks, while the sham group did not show a significant improvement.

Patients had more than 8 months of failed conservative care and a pain score of at least 4 on a visual analogue scale; the mean starting score was 6.9. Thirteen were randomized to active treatment and 12 to sham, and two sham patients were lost to follow-up. A blinded investigator assessed pain at 1, 6 and 12 weeks. Pain fell significantly from baseline in the active group (p < 0.0001), while the change in the sham group was not significant at 12 weeks (p = 0.12). The authors concluded that shockwave is a possible alternative to surgical excision (Fridman, 2009).

This was a small trial. The abstract reports within-group changes rather than a direct statistical comparison between the two groups, and it does not specify whether radial or focused shockwave was used.

The 2016 randomized sham-controlled trial

A second randomized sham-controlled trial found significant improvement in pain and AOFAS lesser-toe scores after ESWT, while the sham group did not improve significantly. Importantly, ultrasound did not show a significant reduction in neuroma diameter.

As summarized in a later systematic review, 14 patients received a single active session of 1,000 shocks at 3 Hz with energy set to maximum tolerance (0.12 to 0.24 mJ/mm²), and 12 received a sham session at 0.03 mJ/mm² with the probe turned away from the target (Matthews, 2019). Pain was measured at 1 and 4 weeks and function at 4 weeks. In the active group, pain was significantly lower at both time points and AOFAS scores were significantly better at 4 weeks. The sham group showed no significant change. Neither group showed a significant change in patient satisfaction or in neuroma diameter on ultrasound, and the authors concluded that ESWT may reduce pain in Morton's neuroma (Seok, 2016).

Follow-up was only four weeks, so the trial says nothing about long-term results.

Symptoms improve; the neuroma does not shrink

ESWT may reduce pain. ESWT has not been shown to shrink the neuroma. In the 2016 trial, symptoms improved while neuroma diameter did not change significantly, and a randomized trial in painful amputation-stump neuroma, described below, also found no significant change in neuroma size despite less pain. The clinical effect may involve pain modulation and local tissue responses rather than physical removal of the nerve enlargement. Shockwave is not used to destroy the nerve, and it should not be described as dissolving, removing or permanently decompressing a neuroma.

What the systematic reviews add

A broader foot-and-ankle systematic review also included Morton's neuroma among conditions with supportive ESWT data, although the strength of evidence varies considerably by diagnosis. It identified 24 clinical studies, 12 randomized trials and 12 case series, across several foot and ankle disorders; only plantar fasciitis had enough trials for a pooled analysis, and the authors called for better studies in Morton's neuroma (Tengku Yusof, 2022).

A systematic review of nonoperative Morton's-neuroma treatment found that shockwave evidence remained limited because the underlying trials were small. When the review compared ESWT with control directly, the difference in pain was not statistically significant (mean difference −5.9 on a 100-point scale, 95% CI −21.9 to 10.1), and the estimate for treatment success was very imprecise. The review found the strongest evidence for corticosteroid injection and for manipulation and mobilization, and concluded that high-quality evidence for a gold-standard intervention was lacking (Matthews, 2019).

This is why the direct randomized data are encouraging but not yet definitive. Two small sham-controlled trials show pain improving after active shockwave and not after sham, but the between-group effect is uncertain and long-term data are sparse.

Painful neuroma evidence outside the foot

Randomized evidence also suggests ESWT can reduce pain in other painful neuroma conditions, which supports biological plausibility, but amputation-stump neuroma is not the same diagnosis as Morton's neuroma. In that trial, 30 patients were randomized to three weekly ultrasound-guided sessions of 1,500 pulses at 0.10 mJ/mm², delivered with an electromagnetic device, or to TENS, desensitization and medication. Pain scores improved significantly more with ESWT, while neuroma size did not differ between groups (Jung, 2014).

The trials at a glance

Radial or focused?

Neither Morton's neuroma trial is described as radial or focused in the information available, so this article calls both simply ESWT. The 2016 trial reported energy flux density, but that alone does not establish the device type. The evidence therefore supports shockwave for Morton's neuroma as a general modality, without establishing whether radial or focused delivery is better.

Why there is no universal protocol

Published protocols differ in energy, pulse number, treatment schedule and localization, so there is not one universally established Morton's-neuroma shockwave protocol. The 2016 trial used a single session, while other neuroma research used weekly sessions. Patients and clinicians should be wary of any claim that a set number of sessions is proven for this condition.

What about EMTT?

Direct clinical evidence for EMTT specifically in Morton's neuroma remains insufficient. EMTT has emerging evidence in other foot and musculoskeletal conditions, but those studies should not be converted into a Morton's-neuroma efficacy claim.

An early prospective pilot in midfoot osteoarthritis reported pain improvement after EMTT, but the study involved only eight patients, had no control group and did not study Morton's neuroma. Its 13 feet received eight sessions over four weeks; pain changed significantly over time, although the comparison of baseline with each follow-up point was not statistically significant, while function improved significantly (Charles, 2026).

A 2026 two-patient report described combined focused ESWT and EMTT for Freiberg disease, but this cannot establish the independent efficacy of EMTT and should not be generalized to Morton's neuroma (Katz, 2026).

In a matched case-control pilot after foot and ankle surgery, 10 patients receiving focused ESWT plus EMTT had lower pain, faster return to activity and more early radiographic healing than 10 controls (Saxena, 2025). Small combination studies suggest EMTT may have biologic potential in foot and ankle rehabilitation, but they do not establish a direct Morton's-neuroma effect. Novo does not present EMTT as an established Morton's-neuroma treatment.

Stress fractures are a separate question

Focused ESWT also has emerging evidence in some bone-stress injuries, but this represents a different biological indication from Morton's neuroma. In a pilot randomized trial of 18 soccer players with proximal fifth metatarsal stress fractures, high-energy focused shockwave and surgical screw fixation showed no statistically significant differences in healing, pain, function or return to play (Ramon, 2023). A suspected stress fracture needs its own diagnosis and imaging, and neuroma or tendon protocols are not applied to it.

Plantar plate injury and generic metatarsalgia

Direct evidence that shockwave repairs plantar plate tears has not been established, and structural MTP instability needs diagnosis and mechanical management first. Generic metatarsalgia is not a shockwave indication on its own.

Where shockwave fits with other care

Shockwave works best as part of a broader plan: wider footwear, forefoot offloading or a metatarsal pad, orthotic support where mechanically indicated, calf and foot rehabilitation, and attention to activity load. The goal of orthotic treatment is to redistribute load, not to claim that a device removes the neuroma. Manual treatment may help surrounding mechanical restrictions, but it does not remove an interdigital neuroma or repair an unstable plantar plate. Persistent symptoms may justify an injection or surgical opinion.

Who might be a candidate

The best candidates have a clinically and, when needed, radiologically supported Morton's neuroma with persistent symptoms despite footwear changes and offloading, after bursitis, plantar plate injury, stress injury and broader nerve problems have been considered. Expectations should be framed around symptom relief rather than removal of the neuroma.

The bottom line

Shockwave has direct, randomized, sham-controlled evidence for Morton's neuroma, but the trials are small, follow-up is short and the between-group effect is uncertain. ESWT may reduce symptoms; it has not been shown to shrink, remove or destroy the neuroma. It is an evidence-supported option, not a definitive cure. EMTT does not yet have direct Morton's-neuroma efficacy data.

How Novo uses this evidence

We first localize forefoot pain to the nerve, bursa, plantar plate, joint, bone or loading pattern. When Morton's neuroma is supported and conservative measures have not been enough, shockwave may be added to footwear, offloading and rehabilitation. See how we approach forefoot pain, metatarsalgia and Morton's neuroma.

References

• Fridman R, Cain JD, Weil L Jr. Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. Journal of the American Podiatric Medical Association. 2009;99(3):191-193. PMID 19448168. (link)
• Seok H, Kim SH, Lee SY, Park SW. Extracorporeal shockwave therapy in patients with Morton's neuroma: a randomized, placebo-controlled trial. Journal of the American Podiatric Medical Association. 2016;106(2):93-99. PMID 27031544. (link)
• Tengku Yusof TNB, Seow D, Vig KS. Extracorporeal shockwave therapy for foot and ankle disorders: a systematic review and meta-analysis. Journal of the American Podiatric Medical Association. 2022;112(3). PMID 34878537. (link)
• Matthews BG, Hurn SE, Harding MP, Henry RA, Ware RS. The effectiveness of non-surgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. Journal of Foot and Ankle Research. 2019;12:12. PMID 30809275. (link)
• Jung YJ, Park WY, Jeon JH, Mun JH, Cho YS, Jun AY, et al. Outcomes of ultrasound-guided extracorporeal shock wave therapy for painful stump neuroma. Annals of Rehabilitation Medicine. 2014;38(4):523-533. PMID 25229031. (link)
• Charles R, Vlasak A, Bondi E. Extracorporeal magnetotransduction therapy (EMTT) for midfoot osteoarthritis: a prospective pilot study of pain and functional outcomes. Journal of the American Podiatric Medical Association. 2026;116(4). PMID 42496340. (link)
• Katz NB, Karnovsky SC, Su JK, Beling AG, Katz G, Berke A, et al. Extracorporeal shockwave therapy with extracorporeal magnetotransduction therapy for osteonecrosis of the metatarsal head: a case series. Foot & Ankle Specialist. Published online 2026. PMID 41723804. (link)
• Saxena A, Bondi E, Gerdesmeyer L, Leal C, Knobloch K, Maffulli N, et al. Focused shock wave therapy (ESWT) and electromagnetic transduction therapy (EMTT) may improve post-operative bone healing in selective foot and ankle surgeries: a case-control pilot study. Journal of Orthopaedic Surgery and Research. 2025;20(1):1018. PMID 41267064. (link)
• Ramon S, Lucenteforte G, Alentorn-Geli E, Steinbacher G, Unzurrunzaga R, Álvarez-Díaz P, et al. Shockwave treatment vs surgery for proximal fifth metatarsal stress fractures in soccer players: a pilot study. Foot & Ankle International. 2023;44(12):1256-1265. PMID 37905784. (link)